Pay transparency laws have reached a tipping point for the life sciences industry. As of early 2026, salary disclosure requirements cover approximately 40% of the US pharmaceutical and biotech workforce, concentrated in the states where life sciences hiring is most active: California, New York, Massachusetts, New Jersey, Colorado, and Washington. For an industry that has historically operated with extreme opacity around executive compensation — where the same VP Regulatory Affairs title can carry total compensation ranging from $220K to $500K depending on company stage, therapeutic area, and equity structure — mandated salary disclosure is forcing a reckoning with how companies communicate, compete for, and retain senior talent.
This analysis draws on our experience across 67 life sciences placements in transparency-law states during 2025, supplemented by conversations with compensation committees, HR leaders, and candidates who are navigating the new landscape. The effects are more nuanced than the headlines suggest, and the implications for senior life sciences professionals are genuinely strategic.
State-by-state requirements for pharma hub states
The transparency requirements vary meaningfully across the states that matter most for life sciences hiring, and understanding the specific requirements in each jurisdiction is essential for both employers and candidates.
California requires salary ranges on all job postings and additionally requires employers to provide the pay scale for a current employee’s position upon request. For the San Francisco and San Diego biotech clusters, this means that every posted clinical, regulatory, and commercial role must include a good-faith salary range. California’s law applies to companies with 15+ employees and covers both base salary and, uniquely, requires disclosure of other forms of compensation if they exist.
New York (both NYC and state) requires salary ranges on postings for roles that will be performed in the state. For the significant concentration of pharma headquarters in Manhattan and the biotech companies in the boroughs and Westchester, this covers the full spectrum of executive hiring. The New York requirements apply to companies with 4+ employees, making it one of the broadest in scope.
Massachusetts took effect in late 2025 with requirements that employers with 25+ employees provide pay ranges on job postings and submit annual wage data reports broken down by race, ethnicity, sex, and job category. For the Cambridge/Boston biotech corridor — the densest concentration of biotech executive hiring in the United States — this has created a new data-reporting obligation that is still being operationalized by most companies.
New Jersey requires salary ranges effective mid-2025 for employers with 10+ employees. Given the massive concentration of pharmaceutical companies along the central New Jersey corridor (Merck, J&J, Novartis, and dozens of mid-sized firms), this law affects a disproportionate share of the US pharmaceutical workforce.
Colorado and Washington were early movers, and the biotech presence in both states (particularly the Seattle area for Washington) means the laws affect a meaningful number of life sciences professionals.
How salary bands affect biotech competitive hiring
The practical impact of salary transparency on biotech competitive hiring has been more complex than either advocates or critics predicted. Three dynamics have emerged that are specific to the life sciences sector:
First, wide ranges have become the norm for life sciences postings. Because a single title like "VP Clinical Operations" can span from a 20-person pre-clinical company to a 500-person commercial-stage company, many life sciences employers post ranges that are legitimately wide. A range of "$250,000 to $380,000" for VP Clinical Ops is not evidence of bad faith — it reflects the genuine internal variance across the company’s clinical programs and the scope of the specific role. However, candidates who don’t understand the stage-based compensation framework often anchor to the top of the posted range regardless of the specific role’s scope, creating friction in the hiring process.
Second, transparency has compressed salary differentials within company tiers. When multiple clinical-stage biotechs in the Cambridge market all post VP Regulatory ranges that are visible to candidates and to competing employers, the outliers — both low and high — adjust toward the mean. We’ve observed a 12% to 15% narrowing of the interquartile range for VP-level life sciences base salaries in transparency-law states compared to non-transparency states. The effect is stronger at the VP level than at the C-suite level, where equity structure varies too widely for base salary disclosure alone to drive meaningful convergence.
Third, clinical-stage biotechs have become more explicit about equity in conversations, even when not legally required to disclose it. Because the posted base salary range for a biotech VP is often 20% to 30% below the base salary range for a comparable big pharma role, biotechs have learned that they need to proactively communicate the equity opportunity in the job posting or early-stage conversations to avoid losing candidates who see only the base range and self-select out. This has had the net positive effect of making the total compensation picture more transparent even beyond what the law strictly requires.
Impact on equity disclosure
The most significant gap in current transparency laws, from a life sciences perspective, is the treatment of equity compensation. Most state laws require disclosure of base salary ranges and, in some cases, bonus targets. Almost none require disclosure of equity grant ranges, option pools, or the methodology used to value equity at the time of hire.
For an industry where equity routinely represents 30% to 60% of total compensation for VP-level and above executives, this gap means that posted salary ranges capture a minority of the compensation picture. A biotech VP role posting "$250K–$320K" in base salary may carry total compensation of $400K to $700K depending on the equity grant — and the candidate has no way to know this from the posting alone.
The practical consequence is a two-tier information system. Base salary transparency gives candidates accurate information about the cash component but leaves the equity component — which is often more valuable and more variable — opaque until deep in the interview process. This creates an information asymmetry that disadvantages candidates who are less experienced in biotech compensation structures and advantages those who know to ask the right questions about equity early in the process.
For life sciences professionals navigating this environment, the recommended approach is direct: ask about equity parameters in the first substantive conversation, not at the offer stage. Questions like "Can you share the typical equity grant range for this level?" and "What is the current 409A valuation relative to the last preferred round?" are legitimate professional questions that sophisticated hiring teams expect and respect.
The recruiter’s perspective
From our vantage point as life sciences executive recruiters operating across multiple transparency-law jurisdictions, three practical observations:
Transparency has accelerated the early stages of the hiring process. Candidates who can see the salary range before applying self-select more effectively, which means the candidates who do engage are more likely to be genuinely interested and within the compensation parameters. Our time-to-shortlist for VP-level life sciences roles in transparency states has decreased by approximately 15% compared to equivalent roles in non-transparency states.
Transparency has not eliminated compensation negotiation. If anything, it has shifted negotiation from base salary (which is now anchored by the posted range) to equity, sign-on bonuses, and non-cash benefits. The total amount of negotiation activity in our life sciences placements has not decreased; it has moved to different components of the package. Candidates who understand this shift negotiate more effectively than those who focus exclusively on base salary.
Transparency has made it harder for companies to lowball. In the pre-transparency era, a biotech company could offer a VP candidate a base salary that was 15% below market and defend it by claiming that "this is what we pay for this role." With published ranges from competitors visible to candidates, below-market offers are immediately identifiable and candidates push back with specific comparable data. This has been net positive for candidates and has forced companies to be more honest about their competitive position.
Implications for senior life sciences candidates
For senior life sciences professionals, pay transparency creates three specific strategic opportunities:
Use posted ranges to benchmark across employer types. When you can see that a big pharma company posts "$340K–$420K" for a VP Regulatory role and a clinical-stage biotech posts "$260K–$330K" for the same title, you have immediate visibility into the cash compensation trade-off between employer types. This information was previously available only through recruiter conversations or informal networks. Use it to make more informed decisions about which employer type aligns with your compensation preferences and risk tolerance.
Anchor negotiations to equity, not base. In transparency-law states, the base salary range is a known quantity. The equity component is where the real variance — and the real negotiating leverage — lives. Prepare for equity negotiations with the same rigor you would previously have applied to base salary negotiations: research comparable equity grants at similar-stage companies, understand the company’s fully diluted share count, and evaluate the equity using realistic assumptions about the company’s trajectory rather than optimistic projections.
Treat transparency data as intelligence, not as limits. Posted ranges represent what the company has publicly committed to as a good-faith range. They do not represent the ceiling of what the company can or will pay. In our experience, approximately 25% of life sciences executive offers in transparency states land above the top of the posted range, typically through equity grants, sign-on bonuses, or title adjustments that move the role into a higher band. The posted range is the starting point of the conversation, not the ending point.
Where transparency is heading
The direction of travel is clear: more states will adopt transparency requirements, the scope of required disclosure will expand, and the life sciences industry will adapt. Several developments are worth watching:
Equity disclosure requirements are coming. Several state legislatures are considering amendments that would extend disclosure requirements to include equity compensation ranges. California’s existing law already hints at this by requiring disclosure of "other forms of compensation." As these requirements expand, the information asymmetry that currently characterizes biotech executive hiring will narrow significantly.
Pay-equity auditing will increase. Massachusetts’s annual wage data reporting requirement is a leading indicator of where other states are headed. For life sciences companies with wide internal pay variance — which is common given the stage-based compensation framework — these reporting requirements will create new compliance obligations and, potentially, new litigation exposure for companies that cannot justify their internal pay disparities.
For life sciences employers, the strategic response is proactive: develop transparent, defensible compensation frameworks before the law requires it. For candidates, the strategic response is informed: use the data that transparency provides, ask the questions that transparency doesn’t yet answer, and negotiate the components that remain outside the published range.
This piece is authored by Catherine Harrington (Talent Partner) with contributions from Malcolm Sheffield on life sciences compensation data and the Alden Search research team.